

SYNTHESIS OF THROMBOXANE A<sub>2</sub> ANALOGUE(±)-(9, 11),(11, 12)-DIDEOXA-(9, 11a)-OXA THROMBOXANE A<sub>2</sub>

Tetsuji Kametani\*

Pharmaceutical Institute, Tohoku University, Aobayama, Sendai 980, Japan


Toshio Suzuki, Akiko Tomino, Shinko Kamada, and Katsuo Unno

Department of Pharmacy, Akita University, Hondo, Akita 010, Japan

**Summary** A synthesis of the thromboxane A<sub>2</sub> analogue, (±)-(9, 11),(11, 12)-dideoxa-(9, 11a)-oxa-thromboxane A<sub>2</sub> (TXA<sub>2</sub>) starting from the exo-adduct **3** of maleic anhydride and furan is described.

Thromboxane A<sub>2</sub> (TXA<sub>2</sub>) generated by incubation of human blood platelet and the prostaglandin H<sub>2</sub> (PGH<sub>2</sub>)<sup>1,2</sup> is an extremely labile substance with potent blood platelet aggregating and vasoconstrictor properties.<sup>3,4</sup> Samuelsson et al.<sup>1</sup> assigned its structure to be **1**, on the basis of several trapping experiments and physiological property, although the whole structure of TXA<sub>2</sub> has not yet been confirmed directly. Since TXA<sub>2</sub> possesses an interesting spectrum of biological activity coupled with its lability, synthetic chemists have focussed on obtaining the stable TXA<sub>2</sub> analogues.<sup>5</sup> Here we wish to report the total synthesis of the stable TXA<sub>2</sub> analogue **2** starting from the exo-adduct **3** of maleic anhydride and furan.


Scheme 1



The first key intermediate **10** was prepared from  $\gamma$ -butyrolactone **4** in 6 steps in 45.7% overall yield. The  $\gamma$ -butyrolactone **4**,<sup>6</sup> derived from the anhydride **3** by sodium borohydride reduction, was hydrogenated over 5% palladium-carbon in methanol to provide **5**,<sup>7</sup> mp 115 ~ 117<sup>o</sup> [95.3%,  $\nu_{\text{max}}$  1760

$\text{cm}^{-1}$ ,  $m/e$  154 ( $M^+$ )]. Treatment of  $\bar{5}$  with potassium cyanide in dimethyl sulfoxide at  $190^\circ$  for 4.5 h gave the cyanated carboxylic acid  $\bar{6}$ . Without further purification, the crude carboxylic acid  $\bar{6}$  was treated with diazomethane to afford the corresponding  $\alpha$ -methyl ester  $\bar{7}$ ,  $mp$   $88 \sim 89^\circ$  [62.7 % from  $\bar{5}$ ,  $\nu_{\max}$  2260, 1725  $\text{cm}^{-1}$ ,  $\delta$  3.75 (3H, s,  $\text{OCH}_3$ ),  $m/e$  195 ( $M^+$ )]. Epimerisation of the  $\alpha$ -isomer  $\bar{7}$  to the  $\beta$ -isomer  $\bar{8}$ ,  $mp$   $65 \sim 67^\circ$  (97.1 %,  $\nu_{\max}$  2260, 1725  $\text{cm}^{-1}$ ,  $\delta$  3.66 (3H, s,  $\text{OCH}_3$ ),  $m/e$  195 ( $M^+$ )] in methanolic potassium carbonate at  $0^\circ$  for 4 h proceeded smoothly. Reduction of the ester  $\bar{8}$  by sodium borohydride in methanol at room temperature for 2 h, followed by oxidation<sup>8</sup> of the resulting alcohol with *N*-chlorosuccinimide, dimethyl sulfide and triethylamine provided the aldehyde  $\bar{10}$  [72.5 % from  $\bar{8}$ ,  $\nu_{\max}$  2260, 1720  $\text{cm}^{-1}$ ,  $\delta$  9.67 (1H, s,  $\text{CHO}$ )]. Since the desired aldehyde  $\bar{10}$  was in our hands, the extension of  $\alpha$ - and  $\beta$ -side chains was carried out as described below. The  $\beta$ -side chain of the

Scheme 2



thromboxane molecule was introduced by condensation of  $\lambda_{10}$  with the sodium salt of dimethyl 2-oxoheptylphosphonate<sup>9</sup> in benzene at room temperature for 2 h. Reduction of the resulting enone  $\lambda_{11}$  [56.8 %,  $\nu_{\max}$  2260, 1700, 1670, 1625  $\text{cm}^{-1}$ ,  $\delta$  6.10 (1H, d,  $J = 16$  Hz, olefinic proton), 6.60 (1H, d, d,  $J = 16, 8$  Hz, olefinic proton), m/e 261 ( $M^+$ )] was carried out using sodium borohydride in methanol at  $0^\circ$  to afford the allyl alcohol  $\lambda_{12}$  as a mixture of diastereoisomers [in quantitative yield,  $\nu_{\max}$  3600 ~ 3200, 2260  $\text{cm}^{-1}$ ,  $\delta$  5.70 (1H, d, d,  $J = 16, 2$  Hz, olefinic proton), 5.33 (1H, d,  $J = 16$  Hz, olefinic proton), 4.57 ~ 3.83 (4H, m,  $C_9H$ ,  $C_{11a}H$ ,  $C_{15}H$ ,  $OH$ )]. Without separation of this mixture, the hydroxy group of  $\lambda_{12}$  was protected as its tetrahydropyranyl ether. Reduction of  $\lambda_{13}$  with diisobutylaluminium hydride (6 eq.) at  $-60^\circ$  for 4 h, followed by a treatment of the mixture with saturated ammonium chloride solution produced the aldehyde  $\lambda_{14}$  [ $\nu_{\max}$  1725  $\text{cm}^{-1}$ ,  $\delta$  9.87 (1H, s,  $CHO$ )]. The Wittig reaction of the aldehyde  $\lambda_{14}$  with the ylide, derived from 5-triphenylphosphoniopentanoic acid, in dimethyl sulfoxide gave a mixture of C-15 diastereoisomeric acids  $\lambda_{15}$  [50.2 % from  $\lambda_{14}$ ,  $\nu_{\max}$  1700  $\text{cm}^{-1}$ ,  $\delta$  9.73 (1H, br s,  $CO_2H$ , exchanged with  $D_2O$ ), 5.76 ~ 5.0 (4H, m, olefinic protons), m/e 333 ( $M^+ - 101$ )], after purification on silica gel column chromatography. Cleavage of the tetrahydropyranyl group with acetic acid-water-tetrahydrofuran (20 : 10 : 3) at  $40^\circ$ , followed by separation of C-15 epimers by preparative tlc ( $CHCl_3 - MeOH$ , 9.5 : 0.5) afforded the desired acids  $\lambda_{16}$  and its C-15 epimer  $\lambda_{17}$  (ca. 1 : 1) [ $\lambda_{16}$ ,  $\nu_{\max}$  3600 ~ 3200, 1710  $\text{cm}^{-1}$ ,  $\delta$  5.68 ~ 5.23 (4H, m, olefinic protons), 5.30 ~ 4.93 (2H,  $CO_2H$ ,  $OH$ , exchanged with  $D_2O$ ), 4.53 ~ 3.90 (3H, m,  $C_9H$ ,  $C_{11a}H$ ,  $C_{15}H$ ), m/e 332 ( $M^+ - 18$ );  $\lambda_{17}$ ,  $\nu_{\max}$  3600 ~ 3200, 1710  $\text{cm}^{-1}$ ,  $\delta$  5.63 ~ 5.23 (4H, m, olefinic protons), 5.33 ~ 5.03 (2H,  $CO_2H$ ,  $OH$  exchanged with  $D_2O$ ), 4.53 ~ 3.90 (3H, m,  $C_9H$ ,  $C_{11a}H$ ,  $C_{15}H$ ), m/e 332 ( $M^+ - 18$ )]. The more polar compound was tentatively assigned the (15S) natural configuration<sup>5,9,10</sup> by comparison with mobility on tlc plate (Rf 0.35 on silica gel with  $CHCl_3 - MeOH$  9.5 : 0.5; Rf 0.39 for less polar compound). In general, this fact has been observed in the field of prostaglandins.

The synthetic method described herein would provide a versatile method for stable thromboxane analogues which involve another heteroatom such as nitrogen and sulphur at the position of bridge-head.

Acknowledgements We would like to express our thanks to Ono Pharmaceutical Co. Ltd., for the donation of 5-triphenylphosphoniopentanoic acid.

#### References and notes

1. M. Hamberg, J. Svensson, and B. Samuelsson, Prod. Natl. Acad. Sci., USA, 72, 2994 (1975).
2. For review, see B. Samuelsson, M. Goldyne, E. Granstrom, M. Hamberg, S. Hamnerstrom, and C. Malmsten, Ann. Rev. Biochem., 47, 997 (1978).
3. P. Needleman, S. Moncada, S. Bunting, J. R. Vane, M. Hamberg, and B. Samuelsson, Nature, 261, 588 (1976).
4. P. Needleman, P. Kulkarni, and A. Raz, Science, 195, 409 (1977).
5. K. M. Maxey and G. L. Bundy, Tetrahedron Lett., 1980, 445; M. Shibasaki, A. Nishida, and S. Ikegami, ibid., 1980, 3061; E. J. Corey, J. W. Ponder, and P. Ulrich, ibid., 1980, 137; S. Onuchida, N. Hamanaka, and M. Hayashi, ibid., 1979, 3661; K. C. Nicolaou, R. L. Magolda, and D. A. Claremon, J. Amer. Chem. Soc., 102, 1404 (1980); K. C. Nicolaou, R. L. Magolda, J. B. Smith, D. Aharony, E. F. Smith, and A. M. Lefer, Proc. Natl. Acad. Sci., USA, 76, 2566 (1979); M. F. Ansell, M. P. L. Caton, M. N. Palfreyman, and K. A. J. Stuttle, Tetrahedron Lett., 1979, 4497; P. Barraclough, ibid., 1980, 1897.
6. S. Takano and K. Ogasawara, Synthesis, 1974, 42.
7. Correct elemental analyses were obtained for this compound.
8. E. J. Corey and C. U. Kim, J. Amer. Chem. Soc., 94, 7586 (1972).
9. E. J. Corey, N. M. Weinschenker, T. K. Schaaf, and W. Huber, J. Amer. Chem. Soc., 91, 5675 (1969).
10. E. J. Corey, K. Narasaka, and M. Shibasaki, J. Amer. Chem. Soc., 98, 6417 (1976).

Received, 18th February, 1981